Skip to content
Research Article Open access CC BY 4.0

Analysis of Renal Platinum Content as a Novel Approach to Protect against Cisplatin Nephrotoxicity: A Review

Yasmen F. Mahran, Omkulthom M. Al Kamaly

Journal of Pharmaceutical Research International · pp. 22–35 · Published 26 Feb 2021

10.9734/jpri/2021/v33i531178

Abstract

Cisplatin (cis-diamine-dichloroplatinum (II), CDDP) is a prominent member of the effective broad-spectrum antitumor drugs. However, its clinical usage is restricted due to serious side effects particularly nephrotoxicity. The vulnerability of the kidney to CDDP is almost certainly related to its primary role in the excretion of the drug as intact CDDP and its platinum containing products are excreted mainly in the urine. There is a correlation between the level of platinum in urine and nephrotoxicity because of renal uptake of the drug. Some analytical methods were applied for the determination of platinum content in biological fluids such as plasma, urine, serum, and peritoneal fluid. Studies have not documented a strong correlation between the renoprotective mechanism and the diminution of renal platinum content.

Amino acids cisplatin HPLC nephrotoxicity novel renoprotective renal uptake.

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.